BioWorld

Sep. 9, 2009

View Archived Issues

Regulatory Submissions Data System Integration: How to Do it

NewCo News: Kinaris Targeting Myosins with Allosteric Inhibitors

Other News To Note

Financings Roundup

Clinic Roundup

Appointments And Advancements

Opexa Gets Boost on Positive Analysis of Tovaxin MS Data

Shares of Opexa Therapeutics Inc. soared 270 percent Tuesday on news of a positive complete analysis of its Phase IIb drug for multiple sclerosis, Tovaxin. (BioWorld Today) Read More

Osiris Sees Prochymal Promise Despite Phase III GvHD Failures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...